Comparative Evaluation of Gastrointestinal Symptoms among Adult users of Pantoprazole and Omeprazole: A Community Survey with WHO Vigi Access Context

Background: Proton pump inhibitors (PPIs), including pantoprazole and omeprazole, are commonly used to treat acidrelated disorders. Gastrointestinal symptoms may occur during treatment, but patient-reported symptoms do not necessarily establish an adverse drug reaction. Methods: This cross-sectional observational community survey included 100 adults from Bengaluru, comprising 50 physical proformas and 50 digital responses. The sample included 74 pantoprazole users and 26 omeprazole users. Demographic information, medicine use and reported gastrointestinal symptoms were summarized using descriptive frequencies and percentages. The dissertation also recorded global spontaneous-reporting counts for selected gastrointestinal events from WHO VigiAccess. Results: New or suspected gastrointestinal discomfort was recorded in 27.0% of pantoprazole users and 23.1% of omeprazole users. In the pantoprazole group, the dissertation’s symptom summary recorded abdominal pain/cramping (9.5%), bloating/gas/flatulence (6.8%), diarrhoea/loose stools (6.8%) and nausea (1.4%). In the omeprazole group, bloating/gas/flatulence and diarrhoea/loose stools were each recorded in 7.7%, nausea in 3.8%, and abdominal pain was not recorded. The VigiAccess extraction log listed 24,546 gastrointestinal disorder reports for pantoprazole and 38,702 for omeprazole. Conclusion: Symptoms were reported in both groups, but the descriptive design, unequal group sizes and absence of diagnostic testing do not establish causality, statistical significance or comparative risk. VigiAccess report counts are not incidence rates.

Authors

Publication Details

Journal
International Journal of Modern Science and Research Technology
Published
2026-11-14
DOI
https://doi.org/10.67317/ijmsrt26nov004
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparative Evaluation of Gastrointestinal Symptoms among Adult users of Pantoprazole and Omeprazole: A Community Survey with WHO Vigi Access Context

Sachin Paul, Diksha Das, Shayan Ghosh, Bhavyashree M et al.
International Journal of Modern Science and Research Technology
Pharmacovigilance and Adverse Drug Reactions
article

Comparative Evaluation of Gastrointestinal Symptoms among Adult users of Pantoprazole and Omeprazole: A Community Survey with WHO Vigi Access Context

Sachin Paul, Diksha Das, Shayan Ghosh, Bhavyashree M, Mujahidul Islam Mondal
article en

Abstract

Background: Proton pump inhibitors (PPIs), including pantoprazole and omeprazole, are commonly used to treat acidrelated disorders. Gastrointestinal symptoms may occur during treatment, but patient-reported symptoms do not necessarily establish an adverse drug reaction. Methods: This cross-sectional observational community survey included 100 adults from Bengaluru, comprising 50 physical proformas and 50 digital responses. The sample included 74 pantoprazole users and 26 omeprazole users. Demographic information, medicine use and reported gastrointestinal symptoms were summarized using descriptive frequencies and percentages. The dissertation also recorded global spontaneous-reporting counts for selected gastrointestinal events from WHO VigiAccess. Results: New or suspected gastrointestinal discomfort was recorded in 27.0% of pantoprazole users and 23.1% of omeprazole users. In the pantoprazole group, the dissertation’s symptom summary recorded abdominal pain/cramping (9.5%), bloating/gas/flatulence (6.8%), diarrhoea/loose stools (6.8%) and nausea (1.4%). In the omeprazole group, bloating/gas/flatulence and diarrhoea/loose stools were each recorded in 7.7%, nausea in 3.8%, and abdominal pain was not recorded. The VigiAccess extraction log listed 24,546 gastrointestinal disorder reports for pantoprazole and 38,702 for omeprazole. Conclusion: Symptoms were reported in both groups, but the descriptive design, unequal group sizes and absence of diagnostic testing do not establish causality, statistical significance or comparative risk. VigiAccess report counts are not incidence rates.

International Journal of Modern Science and Research TechnologyVol. 4(11)
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon